Por que o preço das ações de BAUSCH HEALTH COMPANIES está subindo?
Os otimistas dizem
Company guidance
Company guidance exceeded prior analyst estimates, implying management expects stronger top-line growth than the market had anticipated.
Pipeline opportunity — larsucosterol
Investor focus on larsucosterol as a potential first approved treatment for severe alcohol-associated hepatitis could create a meaningful new commercial opportunity if regulatory approval is achieved.
Revenue and product mix
Total revenue surpassed analysts' expectations driven by stronger vision-care sales, indicating diversification of revenue sources beyond core pharmaceuticals.


